QPI-1002预防心脏手术相关急性肾损伤的1期安全性研究
这项首次人体、随机、安慰剂对照、剂量递增的1期研究,在体外循环心脏手术且急性肾损伤风险患者中评估了静脉注射小干扰RNA QPI-1002的安全性、耐受性和药代动力学。共16例受试者接受安慰剂或QPI-1002 0.5、1.5、5、10 mg/kg单次给药,暴露呈剂量比例增加,平均驻留时间10-13分钟,不良事件发生率组间相似,未观察到剂量限制性毒性或安全信号。
要点
- QPI-1002在0.5-10 mg/kg单次静脉给药后安全且耐受良好。
- 药代动力学呈剂量比例,平均驻留时间10-13分钟,血浆清除迅速。
- 未观察到剂量限制性毒性或安全信号,支持进一步开发。
核心结论
- QPI-1002在体外循环心脏手术后急性肾损伤风险患者中安全且耐受良好,未观察到剂量限制性毒性或安全信号。
研究设计与样本
- 首次人体、随机、安慰剂对照、剂量递增的1期研究,共纳入16例受试者。
- 受试者接受安慰剂(n=4)或QPI-1002 0.5 mg/kg(n=3)、1.5 mg/kg(n=3)、5 mg/kg(n=3)、10 mg/kg(n=3)单次静脉给药。
主要发现
- QPI-1002平均最大浓度和从给药至最后可测浓度的时间曲线下面积总体呈剂量比例,暴露随剂量增加而增加。
- 所有4个给药队列的平均平均驻留时间(至最后可测浓度)为10至13分钟。
- 共报告109例不良事件,安慰剂组26例,QPI-1002 0.5、1.5、5.0、10.0 mg/kg组分别为21、19、24、19例。
- 16例受试者中8例经历至少1例严重不良事件:安慰剂组4例(100%),QPI-1002合并组4例(33.3%)。
临床怎么用
- QPI-1002单次静脉给药在0.5-10 mg/kg范围内安全且耐受良好,支持进一步开发用于急性肾损伤预防。
局限性
- 本研究为1期小样本研究,主要评估安全性和药代动力学,未评估肾脏保护疗效。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
INTRODUCTION: Patients undergoing on-pump cardiac surgery are at an increased risk of acute kidney injury. QPI-1002, a small interfering ribonucleic acid, is under clinical development for the prevention of acute kidney injury. The safety, tolerability, and pharmacokinetics of QPI-1002 was evaluated in this first-in-man, Phase 1 study of a small, interfering ribonucleic acid in patients at risk of acute kidney injury after on-pump cardiac surgery. METHODS: In this phase 1 randomized, placebo-controlled dose-escalation study, a single i.v. dose of QPI-1002 was administered in subjects undergoing on-pump cardiac surgery. Subjects received placebo (n = 4), or QPI-1002 in increasing doses of 0.5 mg/kg (n = 3), 1.5 mg/kg (n = 3), 5 mg/kg (n = 3), and 10 mg/kg (n = 3). RESULTS: A total of 16 subjects were enrolled in the study. The average maximum concentration and area under the curve from the time of dosing to the last measurable concentration of QPI-1002 were generally dose proportional, indicating that exposure increased with increasing dose. The average mean residence time (mean residence time to the last measurable concentration) was 10 to 13 minutes in all 4 drug-dosing cohorts. Adverse events occurred at a similar rate in all study groups. Of the total 109 reported adverse events, the events were distributed as 26 in the placebo group and 21, 19, 24, and 19 in the QPI-1002 0.5, 1.5, 5.0, and 10.0 mg/kg groups, respectively. Eight of the 16 subjects experienced at least 1 serious adverse event: 4 (100%) in the placebo group and 4 (33.3%) in the combined QPI-1002 cohorts. DISCUSSION: QPI-1002 was rapidly eliminated from plasma. QPI-1002 was safe and well tolerated across all dose groups. Overall, no dose-limiting toxicities or safety signals were observed in the study. Further development of QPI-1002 for prophylaxis of acute kidney injury is warranted.
引用
- Demirjian S, Ailawadi G, Polinsky M, et al. Safety and Tolerability Study of an Intravenously Administered Small Interfering Ribonucleic Acid (siRNA) Post On-Pump Cardiothoracic Surgery in Patients at Risk of Acute Kidney Injury. Kidney Int Rep. 2017. PMID: 29270490. doi:10.1016/j.ekir.2017.03.016
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。